Exelixis Reveals Preliminary Financial Outcomes for 2024 and Sets Ambitious Goals for 2025
January 13, 2025 - 02:56
ALAMEDA, Calif., January 12, 2025—Exelixis, Inc. has announced its preliminary unaudited financial results for the fiscal year 2024, alongside financial guidance for the upcoming fiscal year 2025. The company is optimistic about the potential for significant advancements in clinical and regulatory efforts, particularly concerning its cabozantinib franchise.
In 2025, Exelixis plans to focus on executing its clinical programs and anticipates multiple data readouts for zanzalintinib, as well as developments across its diverse pipeline of small molecules and biotherapeutics. The company aims to leverage its existing assets while exploring new opportunities to enhance its market position.
With a clear strategy in place, Exelixis is poised for a year of growth, innovation, and impactful milestones that could shape the future of its therapeutic offerings. The commitment to advancing patient care remains at the forefront of Exelixis's mission as it navigates the challenges and opportunities ahead.
MORE NEWS
December 22, 2025 - 03:36
Remembering Lewis Horwitz: A Pioneer in Indie Film FinancingLewis Horwitz, renowned as the `King of Indie Film Finance,` has passed away at the age of 90. His innovative approach to film financing, particularly through deal memos and foreign presales,...
December 21, 2025 - 13:00
Idaho's Budget Crisis: A Legislative ResponsibilityThe ongoing financial crisis in Idaho can be traced back to critical decisions made by the state`s Legislature and the governor. As the state grapples with budgetary shortfalls, it has become...
December 20, 2025 - 22:53
Hallmark Movies: A Beloved Holiday TraditionSchmaltzy and sentimental, even sappy, but definitely a staple of the Christmas season, Hallmark movies have become a holiday tradition for millions of viewers. Each year, the network releases a...
December 20, 2025 - 01:20
Shifting Perspectives on Regions Financial's FutureRecent developments indicate a notable shift in the outlook for Regions Financial as analysts adjust their price target upwards. The new fair value is estimated at approximately $29.12, an increase...